Key clinical point: Baricitinib offers the flexibility of dose down-titration and improvement in atopic dermatitis (AD) signs and symptoms up to treatment week 104 in patients with moderate-to-severe AD.
Major finding: Among patients receiving 4 mg baricitinib, 51.2% and 47.6% achieved or maintained a validated Investigator’s Global Assessment for AD score of 0 or 1 and 82.1%, and 73.8% maintained an Eczema Area and Severity Index 75 response at weeks 52 and 104, respectively. The clinical response was maintained after down-titration to 2 mg baricitinib.
Study details: This sub-study of the BREEZE-AD3 trial included 168 patients with moderate-to-severe AD who were responders or partial responders to 4 mg baricitinib in originating studies and were re-assigned (1:1) to receive 4 or 2 mg baricitinib at week 52.
Disclosures: This study was funded by Eli Lilly and Company under license from Incyte Corporation. Some authors reported ties with various organizations, including Eli Lilly. Four authors declared being employees and stockholders of Eli Lilly.
Source: Thyssen JP et al. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. J Dermatolog Treat. 2023;34(1):2190430 (Apr 5). Doi: 10.1080/09546634.2023.2190430